Mylan's competitors are coming for its share of the market.
Photograph by Jim Bourg — Reuters
By Aric Jenkins
April 1, 2017

Meridian Medical Technologies has issued a nationwide, voluntary recall of its Mylan EpiPen and EpiPen Jr. allergy shots.

The company said that some of devices may contain a defective part that prevents the injector from activating in the event of an allergic reaction.

“While the number of reported failures is small, EpiPen products that potentially contain a defective part are being recalled because of the potential for life-threatening risk if a severe allergic reaction goes untreated,” the company said in a statement.

The recall impacts 13 types of EpiPen and EpiPen Jr. devices that were distributed between Dec. 17, 2015, and July 1, 2016. Mylan says it will replace any of the affected products at no additional price.

The U.S. recall follows an international recall of roughly 81,000 EpiPens in Australia, New Zealand, Europe and Japan in March.

Mylan asked customers to keep and continue to use their current EpiPens until a replacement is secured. The company can be contacted for additional questions at 800-796-9526 or customer.service@mylan.com.

 

SPONSORED FINANCIAL CONTENT

You May Like

EDIT POST